Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Multiple Sclerosis

Free Subscription 30.04.2018 1 AJNR Am J Neuroradiol 1 Arch Phys Med Rehabil 1 Curr Treat Options Neurol 2 J Neuroimmunol 1 J Neurol 7 Mult Scler 4 Neurology 3 PLoS One 1 Rev Neurol 3 Rev Neurol (Paris)

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AJNR Am J Neuroradiol

1. TILLEMA JM, Weigand SD, Dayan M, Shu Y, et al
   Dark Rims: Novel Sequence Enhances Diagnostic Specificity in Multiple Sclerosis.
   AJNR Am J Neuroradiol. 2018 Apr 26. pii: ajnr.A5636. doi: 10.3174/ajnr.A5636.
   PubMed     Text format     Abstract available
   
   

   
   Arch Phys Med Rehabil

2. GUNN H, Cameron M, Hoang P, Lord S, et al
   The relationship between physiological and perceived fall risk in people with multiple sclerosis: Implications for assessment and management.
   Arch Phys Med Rehabil. 2018 Apr 23. pii: S0003-9993(18)30238.
   PubMed     Text format     Abstract available
   
   

   
   Curr Treat Options Neurol

3. JOKUBAITIS VG, Zhou Y, Butzkueven H, Taylor BV, et al
   Genotype and Phenotype in Multiple Sclerosis-Potential for Disease Course Prediction?
   Curr Treat Options Neurol. 2018;20:18.
   PubMed     Text format     Abstract available
   
   

   
   J Neuroimmunol

4. SERAFINI B, Zandee S, Rosicarelli B, Scorsi E, et al
   Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption.
   J Neuroimmunol. 2018;319:9-12.
   PubMed     Text format    
   
   
5. AKAISHI T, Takahashi T, Nakashima I
   Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis.
   J Neuroimmunol. 2018;319:37-40.
   PubMed     Text format     Abstract available
   
   

   
   J Neurol

6. RASUL T, Frederiksen JL
   Link between overweight/obese in children and youngsters and occurrence of multiple sclerosis.
   J Neurol. 2018 Apr 26. pii: 10.1007/s00415-018-8869.
   PubMed     Text format     Abstract available
   
   

   
   Mult Scler

7. CREARY LE, Mallempati KC, Gangavarapu S, Caillier SJ, et al
   Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.
   Mult Scler. 2018 Apr 1:1352458518770019. doi: 10.1177/1352458518770019.
   PubMed     Text format     Abstract available
   
   
8. MCCLURG D, Bugge C, Elders A, Irshad T, et al
   Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.
   Mult Scler. 2018 Apr 1:1352458518768722. doi: 10.1177/1352458518768722.
   PubMed     Text format     Abstract available
   
   
9. WAGLEY S, Bokori-Brown M, Morcrette H, Malaspina A, et al
   Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
   Mult Scler. 2018 Apr 1:1352458518767327. doi: 10.1177/1352458518767327.
   PubMed     Text format     Abstract available
   
   
10. LLUFRIU S, Rocca MA, Pagani E, Riccitelli GC, et al
    Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.
    Mult Scler. 2018 Apr 1:1352458518771838. doi: 10.1177/1352458518771838.
    PubMed     Text format     Abstract available
    
    
11. SAUL A, Taylor B, Simpson S Jr, Ponsonby AL, et al
    Polymorphism in the serotonin transporter gene polymorphisms ( 5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770021. doi: 10.1177/1352458518770021.
    PubMed     Text format     Abstract available
    
    
12. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
    Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768433. doi: 10.1177/1352458518768433.
    PubMed     Text format     Abstract available
    
    
13. MARRIE RA, Montalban X
    Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
    Mult Scler. 2018;24:558-562.
    PubMed     Text format    
    
    

    
    Neurology

14. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:777-788.
    PubMed     Text format     Abstract available
    
    
15. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:789-800.
    PubMed     Text format     Abstract available
    
    
16. BAR-OR A, Grove RA, Austin DJ, Tolson JM, et al
    Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005516.
    PubMed     Text format     Abstract available
    
    
17. GERARDI C, Bertele' V, Rossi S, Garattini S, et al
    Preapproval and postapproval evidence on drugs for multiple sclerosis.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005561.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

18. KLISTORNER A, Wang C, Yiannikas C, Parratt J, et al
    Diffusivity in the core of chronic multiple sclerosis lesions.
    PLoS One. 2018;13:e0194142.
    PubMed     Text format     Abstract available
    
    
19. CHROBOK NL, Bol JGJM, Jongenelen CA, Breve JJP, et al
    Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    PLoS One. 2018;13:e0196433.
    PubMed     Text format     Abstract available
    
    
20. ABDOLLAHPOUR I, Nedjat S, Mansournia MA, Schuster T, et al
    Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population.
    PLoS One. 2018;13:e0196244.
    PubMed     Text format     Abstract available
    
    

    
    Rev Neurol

21. GONZALEZ-GOMEZ A, Garcia-Ben A, Soler-Garcia A, Garcia-Basterra I, et al
    [Analysis of the quantitative differences in the thickness of the retinal nerve fibre layer between time-domain and spectral-domain optical coherence tomography in patients with relapsing-remitting multiple sclerosis].
    Rev Neurol. 2018;66:297-302.
    PubMed     Text format     Abstract available
    
    

    
    Rev Neurol (Paris)

22. DERACHE N, Dufay A, Lebarbey C
    Organization of care for multiple sclerosis in France.
    Rev Neurol (Paris). 2018 Apr 20. pii: S0035-3787(17)30858.
    PubMed     Text format     Abstract available
    
    
23. ZEPHIR H
    Progress in understanding the pathophysiology of multiple sclerosis.
    Rev Neurol (Paris). 2018 Apr 18. pii: S0035-3787(17)30859.
    PubMed     Text format     Abstract available
    
    
24. COHEN M
    Connected health and multiple sclerosis.
    Rev Neurol (Paris). 2018 Apr 18. pii: S0035-3787(17)30794.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: